Document is current
Any future updates will be listed below
-
Authors
Fagiani, Francesca
Pedrini, Edoardo
Martire, Maria Sofia https://orcid.org/0009-0007-7479-2695
Gastoldi, Gaia
Vanden Bulcke, Colin https://orcid.org/0000-0002-2210-1625
Lin, Jing-Ping https://orcid.org/0000-0003-0686-0215
Maric, Dragan https://orcid.org/0000-0003-2912-7921
Brambilla, Elena
Ruffini, Francesca https://orcid.org/0000-0002-2226-6366
Peri, Carolina
Calabresi, Peter A. https://orcid.org/0000-0002-7776-6472
Maggi, Pietro
Panina-Bordignon, Paola https://orcid.org/0000-0001-9913-8568
Martino, Gianvito https://orcid.org/0000-0003-1295-9131
Reich, Daniel S. https://orcid.org/0000-0002-2628-4334
Absinta, Martina https://orcid.org/0000-0003-0276-383X
- License Information
-
More Information
Article History
Received: 15 June 2025
Accepted: 19 August 2025
First Online: 26 September 2025
Competing interests
: P.A.C. received research funding from Genentech and consulting honoraria for serving on advisory boards for Idorsia Spolia Therapeutics and Lilly. P.M. received consulting and/or speaker honoraria from Sanofi, Biogen, and Merck. D.S.R. received research funding from Abata Therapeutics and Sanofi. M.A. received consulting and/or speaker honoraria from GSK, Sanofi, Biogen, Immunic Therapeutics, Viatris, and Abata Therapeutics. All other authors report no relevant declaration of interest.
